The Value Forge

Meta-Analysis

24 July 2026 Meta-analysis NEW Meta-analysis finds remote cardiac rehabilitation matches or exceeds centre-based care for heart failure patients
A meta-analysis of eight randomised trials finds mobile-health-supported remote or hybrid cardiac rehabilitation performs as well as, or better than, centre-based rehabilitation on exercise capacity in heart failure, though certainty is low to moderate.
17 July 2026 Meta-analysis NEW Reablement-based home rehabilitation shows weak evidence of benefit, meta-analysis finds
A GRADE-assessed systematic review and meta-analysis of 27 trials finds reablement-based home rehabilitation has low-to-very-low-certainty evidence of improving daily function, while structured exercise-based rehabilitation does show benefit.
17 July 2026 Meta-analysis NEW Pharmacist involvement in OPAT teams cuts prescribing errors, meta-analysis finds
A systematic review and meta-analysis finds pharmacist involvement in OPAT multidisciplinary teams improves monitoring adherence and reduces prescribing errors, though impact on readmissions remains inconsistent.
17 July 2026 Meta-analysis NEW Meta-analysis confirms exercise-based rehabilitation eases depression in rheumatoid arthritis
A meta-analysis of 15 randomised trials finds structured exercise reduces depressive symptoms in rheumatoid arthritis with moderate certainty.
3 July 2026 Meta-analysis NEW Activity- and exercise-based home rehabilitation improves daily function in older adults, meta-analysis finds
A meta-analysis of 27 randomised controlled trials in community-dwelling older adults found activity- and exercise-based home rehabilitation improved daily-living function and physical performance, while reablement-based approaches showed no significant effect.
26 June 2026 Meta-analysisPrimary Study NEW Ceftriaxone associated with threefold mortality increase in MSSA bloodstream infections: implications for OPAT prescribing
A systematic review and meta-analysis of 11 studies (n=2,568) found ceftriaxone associated with significantly increased 30-day mortality (OR 3.33, 95% CI 2.17–5.10) compared with antistaphylococcal penicillins or cefazolin for MSSA bloodstream infections. A concurrent cost analysis of CADD-pump-based OPAT demonstrated 88% cost savings versus inpatient care, providing the delivery mechanism for safer beta-lactam alternatives.